Morteza Esmaeili1,2 and Ovidiu Cristian Andronesi1
1Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, 2Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Synopsis
With
increasing number of high field 7T MR systems in clinical setting, the
potential of using advanced MR modalities such as MR spectroscopy is
increasing. Imaging 2-hydroxyglutarate (2-HG) can genotype IDH mutations in
gliomas. However, the MR signal of this metabolite is overlapped with other
resonances, hampering robust quantification of 2-HG. Here we optimized the
timing of LASER sequence for robust detection of 2-HG at high field 7T in the
presence of B1 inhomogeneity.
TARGET AUDIENCE
MRS sequence developers;
Neuroradiologists; Neuroscientists; Neurologists.PURPOSE
Accumulation of 2-HG metabolite in glioma patients
that harbor isocitrate dehydrogenase (IDH)
mutation is
associated with improved clinical outcome and response to treatment
1. Therefore, unambiguous and robust detection of
this oncometabolite can benefit accurate gliomas stratification and targeted
therapy. Despite recent development of MRS sequences
2-4, improving sensitivity
and specificity of 2-HG
detection is still an area under investigation.
Previous work using PRESS
5 and semi-LASER
4 sequences at 7T have shown that an inverted 2.25
peak can be obtained for 2HG which is distinguishable from modulation of
glutamate and glutamine. However, spectral modulations are very sensitive to
inaccuracies of flip angles which are exacerbated at 7T due to B1
inhomogeneity. In this work we aimed to optimize
a fully adiabatic LASER sequence that can compensate better the B1
inhomogeneity for robust detection of 2-HG at high field 7T.
METHODS
2HG,
Glu, and Gln spectra were simulated for different echo timings of a LASER6
sequence at 7T field strength using GAMMA library. We analyzed the J-coupling modulation
and the intensity of these metabolites for each sequence timing (Fig. 1). In
particular our aim was to maximize the separation of 2.25ppm signal of 2HG from
overlapping resonances. The
LASER sequence consists of three pairs of adiabatic refocusing pulses, which
can be separated in three sub-echo times TE1, TE2, and TE3, respectively. The best
timing combinations for adiabatic refocusing RF pulses in the LASER sequence, i.e.
TE1, TE2 and TE3 combination, were searched (Fig. 1) by simulations to provide
a unique behavior of 2-HG resonances compared with other resonances, such as a
negative intensity and increased amplitude of 2-HG signal with simultaneous decreased
amplitude and opposite modulation of the neighboring metabolite resonances. In
addition, we searched for the combinations that achieved these goals for the
minimum total echo time. The candidate timing intervals in our LASER sequence were verified
experimentally on phantoms containing 10 mM 2-HG and identical concentration of
Glu and Gln, and 20 mM of glycine. In order to reduce specific absorption rate
(SAR) of the LASER we used gradient modulated adiabatic pulses GOIA-W(16,4)6
of 5 ms duration and 20 kHz bandwidth that allowed us in vivo TR of 5s at 7T.RESULTS
A
LASER sequence with TE=90 ms (TE1/TE2/TE3= 15/45/30 ms) provided a large negative
2-HG resonance at 2.25 ppm well separated from those of overlapped resonances. The
same 2HG resonance pattern was observed in MR spectra obtained from phantoms
applying the same timing intervals (Fig. 2), accompanied with reduced levels of overlapping
peaks Glu and Gln (Fig. 3).
DISCUSSION/CONCLUSION
The proposed sequence timing of our LASER sequence
may provide unambiguous detection of 2-HG resonances on a 7T clinical scanner
with high specificity and sensitivity. Our preliminary results from simulations
and phantoms are currently under investigation in patients. Further, this
technique provides a great opportunity to non-invasively monitor the effect of
new anti-cancer drugs that target mutant IDH enzymes.Acknowledgements
No acknowledgement found.References
1. Yan,
H. et al. IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine 360, 765-773 (2009).
2. Choi,
C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in
subjects with IDH-mutated gliomas. Nature
Medicine 18, 624-629 (2012).
3. Andronesi,
O.C. et al. Treatment response assessment in IDH-mutant glioma patients by
non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research 22, 1632-1641 (2016).
4. Emir,
U.E. et al. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas
with IDH1 and IDH2 Mutations. Cancer Res.
76, 43-49. (2016).
5. Ganji,
S.K. et al. In vivo detection of 2-hydroxyglutarate in brain tumors by
optimized point-resolved spectroscopy (PRESS) at 7T. Magn Reson Med doi:
10.1002/mrm.26190 (2016).
6. Andronesi,
O.C. et al. Spectroscopic imaging with improved gradient modulated constant
adiabaticity pulses on high-field clinical scanners. Journal of Magnetic Resonance 203,
283-293 (2010).